CytomX Therapeutics’ (CTMX) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note released on Tuesday morning,Benzinga reports.

CytomX Therapeutics Stock Down 10.5 %

Shares of NASDAQ CTMX opened at $1.02 on Tuesday. The company has a 50 day moving average of $1.06 and a 200 day moving average of $1.17. CytomX Therapeutics has a twelve month low of $0.83 and a twelve month high of $5.85. The firm has a market cap of $79.82 million, a P/E ratio of 6.00 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million for the quarter, compared to the consensus estimate of $18.92 million. During the same period in the prior year, the company posted $0.04 earnings per share. As a group, equities analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. Virtu Financial LLC purchased a new stake in CytomX Therapeutics during the 3rd quarter valued at $104,000. Geode Capital Management LLC increased its position in CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 16,359 shares during the period. FMR LLC boosted its position in CytomX Therapeutics by 17.3% in the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after purchasing an additional 41,949 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares during the period. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.